FDA Approves nivolumab Plus ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

[Miranda_GO2]

This is the eighth drug approval in two months, please email [e-mail] if you have any questions about any of these recent approvals.

On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet chemotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having no changes in EGFR or ALK. The FDA based their approval on the results of the clinical trial CHECKMATE-9LA which showed that patients receiving Opdivo, Yervoy, and two cycles of platinum-doublet chemotherapy lived longer, had a higher chance of responding well to treatment, and went longer periods of time without progression than those receiving chemotherapy by itself.

The combination of Opdivo, Yervoy, and chemotherapy being available as a first line targeted therapy option gives patients more options for first line treatment. Patients are also able to stop chemotherapy after the two cycles and continue with the combination of Opdivo and Yervoy.

Here is the link for full press release: fda.gov/drugs/drug-approval...

[Denzie Moderator Volunteer]

I love it when those clinical trials bear so much fruit. Nether drug us new but the combination is awesome.

[Miranda_GO2 Partner in reply to Denzie]

True. I use the phrasing from our blogs to post approvals, I will try to words the post to clarify if it s a brand new drug that was approved or new use/ line of treatment approval! =)

[Denzie Moderator Volunteer in reply to Miranda_GO2]

But it is an absolutely new use! That makes it awesome!